Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
This piece analyzes whether retirement funds should favor index or target date options, emphasizing long-term planning and goal alignment.
26,209 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
You’ve bought a few rental properties, but the real work starts now. This guide delivers a step-by-step plan to optim...
Citi upgraded AMD to Buy with a $575 price target, sending shares higher and reigniting the AI GPU narrative. Investo...
Robinhood’s Layer-2 push and the launch of perpetual futures on a crypto DEX could shift how retail traders access cr...
Palvella Therapeutics just saw a notable insider move after a multi-hundred percent rally. This guide breaks down the...
A Fulton Financial director sold shares after the stock surged about 26%. This article breaks down what insider sales...
As Microsoft trades off recently, savvy investors look for steady leaders among mega-cap stocks after microsoft's pul...
Mega rounds in drones and AI-driven drug discovery signal big shifts in tech investing. This piece explains the perso...
Intel has surged ahead in 2026, outpacing AMD by more than double in year-to-date gains. The rally prompts investors ...
Dylan Lee’s wedding in Saint-Tropez blends private moments with luxury, offering practical budgeting insights for cou...
Rate expands its mortgage team by bringing 14 loan officers from New American Funding, aiming to boost production and...
For years, Annaly stock drew steady income seekers. Today, a different financial stock could outperform on yield and ...